iA Global Asset Management Inc. Has $1.24 Million Holdings in Insulet Co. (NASDAQ:PODD)

iA Global Asset Management Inc. grew its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 131.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,756 shares of the medical instruments supplier's stock after purchasing an additional 2,698 shares during the quarter. iA Global Asset Management Inc.'s holdings in Insulet were worth $1,242,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. SBI Securities Co. Ltd. bought a new position in Insulet during the 4th quarter worth approximately $36,000. SRS Capital Advisors Inc. raised its position in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial bought a new position in Insulet during the fourth quarter worth $57,000. TD Private Client Wealth LLC lifted its stake in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 56 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares during the period.

Insider Buying and Selling

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.47% of the stock is currently owned by company insiders.

Remove Ads

Insulet Price Performance

PODD stock traded down $1.33 on Tuesday, hitting $272.71. 958,553 shares of the company's stock traded hands, compared to its average volume of 690,204. The stock has a market cap of $19.15 billion, a price-to-earnings ratio of 47.10, a P/E/G ratio of 3.62 and a beta of 1.29. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a fifty day moving average of $272.27 and a 200-day moving average of $258.19.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. JPMorgan Chase & Co. increased their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a report on Thursday, December 12th. Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Raymond James restated an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Royal Bank of Canada began coverage on shares of Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective on the stock. Finally, StockNews.com cut shares of Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.